» Articles » PMID: 17012854

Cutaneous Delivery of a Live, Attenuated Chimeric Flavivirus Vaccine Against Japanese Encephalitis (ChimeriVax)-JE) in Non-human Primates

Overview
Journal Hum Vaccin
Date 2006 Oct 3
PMID 17012854
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Flaviviral diseases such as yellow fever, Japanese encephalitis (JE) and dengue hemorrhagic fever cause enormous morbidity and mortality worldwide. There is an urgent need for alternative technologies for mass vaccination against these and other diseases, particularly in the developing world. Here, we administered a live attenuated, chimeric JE vaccine (ChimeriVax)-JE) to nonhuman primates by skin microabrasion and intradermal delivery using microneedles. Both cutaneous delivery methods induced mild viremia similar in magnitude to that observed following subcutaneous (SC) injection. The duration of viremia induced by cutaneous delivery (5-7 days), however, was substantially longer than via SC (0-3 days). In addition, mean neutralizing antibody titers in cutaneous delivery groups were up to 7-fold greater than via SC injection. There were no safety issues identified and both cutaneous delivery methods appeared to be well tolerated. Thus, cutaneous delivery may represent a minimally-invasive alternative approach for flavivirus vaccines that more closely resembles the natural route of viral infection.

Citing Articles

Current Status of Microneedle Array Technology for Therapeutic Delivery: From Bench to Clinic.

Chakraborty C, Bhattacharya M, Lee S Mol Biotechnol. 2023; 66(12):3415-3437.

PMID: 37987985 DOI: 10.1007/s12033-023-00961-2.


Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.

Roche R, Odeh N, Andar A, Tulapurkar M, Roche J Microorganisms. 2023; 11(8).

PMID: 37630523 PMC: 10459411. DOI: 10.3390/microorganisms11081963.


Microneedles: An Emerging Vaccine Delivery Tool and a Prospective Solution to the Challenges of SARS-CoV-2 Mass Vaccination.

Feng Y, Hu H, Wong Y, Yao X, He M Pharmaceutics. 2023; 15(5).

PMID: 37242591 PMC: 10222661. DOI: 10.3390/pharmaceutics15051349.


Microarray patches enable the development of skin-targeted vaccines against COVID-19.

Korkmaz E, Balmert S, Sumpter T, Donahue Carey C, Erdos G, Falo Jr L Adv Drug Deliv Rev. 2021; 171:164-186.

PMID: 33539853 PMC: 8060128. DOI: 10.1016/j.addr.2021.01.022.


Progress in microneedle array patch (MAP) for vaccine delivery.

Nguyen T, Oh Y, Kim Y, Shin Y, Baek S, Park J Hum Vaccin Immunother. 2020; 17(1):316-327.

PMID: 32667239 PMC: 7872046. DOI: 10.1080/21645515.2020.1767997.